Celecoxib and depression

A clinical trial of adjunctive Celecoxib treatment in patients with major depression: a double-blind, placebo controlled trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711141556N5

Enrollment

Registered

2009-03-13

Start date

2007-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive episode. Depressive episode

Interventions

Intervention 1: Capsule Fluoxetine 40 mg/day plus Capsule Celecoxib 400 mg/day (200 mg bid) as intervention group for 6 weeks. Intervention 2: Cap fluoxetine 40 mg/day plus Cap. placebo as control gr

Treatment - Drugs

Capsule Fluoxetine 40 mg/day plus Capsule Celecoxib 400 mg/day (200 mg bid) as intervention group for 6 weeks

Cap fluoxetine 40 mg/day plus Cap. placebo as control group for 6 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of Major Depressive Disorder based on DSM-IV criteria, Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 18. Exclusion criteria: Presence of Psychosis, any diagnosis in Axis I and II, Receiving psychotropic medications, receiving any antidepressants during past one month or ECT in past two months, Presence of hypothyroidism or cardiovascular problems

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026